The story of how UK Biotech Heptares drives its clinical program after its acquisition by Sosei




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The story of how UK Biotech Heptares drives its clinical program after its acquisition by Sosei
Released on: March 24, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Heptares is a leading UK biotech that was bought earlier this year for up to $400 million by the Japanese company, Sosei Group Corporation.
  • Summary
  • Transcript
  • Participants
  • Company
Heptares is a leading UK biotech that was bought earlier this year for up to $400 million by the Japanese company, Sosei Group Corporation. Malcolm Weir, CEO and Founder of Heptares, talks to Fintan Walton, CEO of PharmaVentures, about the acquisition by Sosei and other recent business activities, such as their recent Immuno-Oncology deal with AstraZeneca.
Heptares is a leading UK biotech that was bought earlier this year for up to $400 million by the Japanese company, Sosei Group Corporation. Malcolm Weir, CEO and Founder of Heptares, talks to Fintan Walton, CEO of PharmaVentures, about the acquisition by Sosei and other recent business activities, such as their recent Immuno-Oncology deal with AstraZeneca.
Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, London. He was Head of the Biomolecular Structure Department and then the Molecular Sciences Division of GlaxoWellcome with responsibility for 300 people engaged in target validation and lead discovery. During this time he led the application of structural biology and modelling to drug discovery, resulting in the advancement of clinical candidates to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 2000, growing it from the spin-out stage to a 100-person company. Inpharmatica was sold to Galapagos NV in 2006. He joined MRC Technology in 2006 in order to establish Heptares Therapeutics Ltd in July 2007, as co-founder and CEO. Malcolm was elected Visiting Professor of Biochemistry at Imperial College, London in 1997 and is on the Chemical Biology Advisory Board at the same university. He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004-2011. Malcolm received the Malcolm Campbell Memorial Prize 2015, awarded by the UK Royal Society of Chemistry’s Biological and Medicinal Chemistry Sector, in recognition of his contribution to GPCR drug discovery.
Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. We are an industry pioneer in GPCR structure-based drug design (SBDD) and have built a powerful and unique capability for discovering both small molecule and antibody medicines targeting GPCRs. Our SBDD platform enables us to unlock GPCRs that have strong clinical and biological validation, yet which have proven to be historically hard to drug